EYPT

RADNOR, Pa., Sept. 6, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by EyePoint, Inc. (NASDAQ: EYPT) on behalf of investors who purchased or acquired EyePoint, Inc. securities and experienced significant financial losses.

RADNOR, Pa., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by EyePoint, Inc. (NASDAQ: EYPT) on behalf of investors who purchased or acquired EyePoint, Inc. securities and experienced significant financial losses.

NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ: EYPT).

NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of EyePoint Pharmaceuticals (“EyePoint” or the “Company”) (NASDAQ: EYPT) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws and other unlawful business practices.

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In EyePoint (EYPT) To Contact Him Directly To Discuss Their Options

WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that the Company will participate at the following upcoming conferences:

NEW YORK--(BUSINESS WIRE)---- $EYPT #ClassActionLawsuit--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of EyePoint Pharmaceuticals (“EyePoint” or the “Company”) (NASDAQ: EYPT) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices.[LEARN MORE ABOUT THE INVESTIGATION]What Happened?On August 14, 2026, EyePoint released topline results in its Phase 3 LUGANO wet AMD trial for DURAVYU.

NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ: EYPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

RADNOR, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by EyePoint, Inc. (NASDAQ: EYPT) on behalf of investors who purchased or acquired EyePoint, Inc. securities and experienced significant financial losses.

NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against EyePoint Pharmaceuticals (“EyePoint” or the “Company”) (NASDAQ: EYPT). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. If you purchased or otherwise acquired EyePoint securities, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to learn more about your rights.